Literature DB >> 3352514

The emerging role of Fusarium infections in patients with cancer.

E Anaissie1, H Kantarjian, J Ro, R Hopfer, K Rolston, V Fainstein, G Bodey.   

Abstract

Infection due to Fusarium species is an increasing cause of serious potentially fatal disease in patients with cancer. We described 9 patients with infection caused by Fusarium species during a 4-year period at the M. D. Anderson Hospital. The spectrum of infections included disseminated disease in 4 patients, skin or soft-tissue infections in 3, pneumonia in 1, and fungemia in 1. All 4 patients with disseminated infection had culture- and biopsy-proven skin lesions caused by Fusarium species and the blood cultures yielded the organism in 3 of these 4 patients. Maxillary sinusitis was the presenting manifestation of Fusarium infection in 2 of these 4 patients, suggesting that paranasal sinuses are potential portals of entry for the infection. Eight patients had a hematological malignancy and 7 were neutropenic at the onset of their infection. Patients with deep-seated infections remained neutropenic and died from infection despite treatment with amphotericin B. All 5 isolates tested in vitro showed resistance to ketoconazole and miconazole, whereas 3 were susceptible to amphotericin B. Fusarium species could play a role in producing myelosuppression and fungal cultures are required to differentiate it from the more commonly encountered Aspergillus species. Fusarium species are emerging as a serious, potentially fatal, pathogen in patients with cancer.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3352514     DOI: 10.1097/00005792-198803000-00001

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  33 in total

1.  In vitro and in vivo experimental activities of antifungal agents against Fusarium solani.

Authors:  J Guarro; I Pujol; E Mayayo
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 2.  Typing tools for the investigation of epidemic fungal infection.

Authors:  S A Howell; W C Noble
Journal:  Epidemiol Infect       Date:  1990-08       Impact factor: 2.451

3.  Antifungal susceptibility of 44 clinical isolates of Fusarium species determined by using a broth microdilution method.

Authors:  A Reuben; E Anaissie; P E Nelson; R Hashem; C Legrand; D H Ho; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

4.  Three cases of infection with Fusarium species in neutropenic patients.

Authors:  M Nucci; N Spector; S Lucena; P C Bacha; W Pulcheri; A Lamosa; A Derossi; M J Caiuby; J Macieira; H P Oliveira
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-12       Impact factor: 3.267

5.  Fungicidal activity of cecropin A.

Authors:  A J DeLucca; J M Bland; T J Jacks; C Grimm; T E Cleveland; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

6.  N-acetylcysteine inhibits germination of conidia and growth of Aspergillus spp. and Fusarium spp.

Authors:  A J De Lucca; T J Walsh; D J Daigle
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

7.  In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species.

Authors:  C J Clancy; M H Nguyen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-08       Impact factor: 3.267

8.  Invasive infection with Fusarium chlamydosporum in a patient with aplastic anemia.

Authors:  B H Segal; T J Walsh; J M Liu; J D Wilson; K J Kwon-Chung
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

Review 9.  Fungal infections: a growing threat.

Authors:  D M Dixon; M M McNeil; M L Cohen; B G Gellin; J R La Montagne
Journal:  Public Health Rep       Date:  1996 May-Jun       Impact factor: 2.792

10.  Interactions between triazoles and amphotericin B in treatment of disseminated murine infection by Fusarium oxysporum.

Authors:  Mery Ruíz-Cendoya; Marçal Mariné; M M Rodríguez; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.